Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Fennec Pharmaceuticals Inc (FENC)

Fennec Pharmaceuticals Inc (FENC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 166,488
  • Shares Outstanding, K 27,428
  • Annual Sales, $ 21,250 K
  • Annual Income, $ -16,050 K
  • EBIT $ 2 M
  • EBITDA $ 2 M
  • 60-Month Beta 0.35
  • Price/Sales 8.04
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 235.45% ( +14.18%)
  • Historical Volatility 89.97%
  • IV Percentile 93%
  • IV Rank 57.26%
  • IV High 394.16% on 10/18/24
  • IV Low 22.77% on 06/14/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 6
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 96
  • Open Int (30-Day) 180

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.11
  • Number of Estimates 2
  • High Estimate -0.05
  • Low Estimate -0.17
  • Prior Year -0.10
  • Growth Rate Est. (year over year) -10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.96 +44.44%
on 11/18/24
6.55 -12.64%
on 11/27/24
+0.92 (+19.17%)
since 11/05/24
3-Month
3.96 +44.44%
on 11/18/24
6.55 -12.64%
on 11/27/24
+0.35 (+6.52%)
since 09/05/24
52-Week
3.96 +44.44%
on 11/18/24
11.92 -52.01%
on 12/28/23
-3.52 (-38.10%)
since 12/05/23

Most Recent Stories

More News
Insider Sale: Director at $FENC (FENC) Sells 6,409 Shares

CHRIS A RALLIS, a director at $FENC ($FENC), sold 6,409 shares of the company on 12-02-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 10.9% of their shares....

FENC : 5.72 (-5.77%)
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

FRX.TO : 8.03 (-6.30%)
FENC : 5.72 (-5.77%)
Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

FRX.TO : 8.03 (-6.30%)
FENC : 5.72 (-5.77%)
Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

FRX.TO : 8.03 (-6.30%)
FENC : 5.72 (-5.77%)
Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company’s Next Stage of Growth

FRX.TO : 8.03 (-6.30%)
FENC : 5.72 (-5.77%)
Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor

~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of...

FRX.TO : 8.03 (-6.30%)
FENC : 5.72 (-5.77%)
Fennec Announces Results of Annual Meeting

RESEARCH TRIANGLE PARK, N.C., June 14, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that...

FENC : 5.72 (-5.77%)
FRX.TO : 8.03 (-6.30%)
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., May 23, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company...

FRX.TO : 8.03 (-6.30%)
FENC : 5.72 (-5.77%)
Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~ ~ If Approved by the FDA, PEDMARKTM Stands to Be the First...

FRX.TO : 8.03 (-6.30%)
FENC : 5.72 (-5.77%)
Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK™

~ Prescription Drug User Fee Act (PDUFA) target action date set for September 23, 2022 ~...

FRX.TO : 8.03 (-6.30%)
FENC : 5.72 (-5.77%)

Business Summary

Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. The Company's products include Eniluracil and Sodium Thiosulfate (STS). Fennec Pharmaceuticals Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 6.53
2nd Resistance Point 6.31
1st Resistance Point 6.01
Last Price 5.72
1st Support Level 5.49
2nd Support Level 5.27
3rd Support Level 4.97

See More

52-Week High 11.92
Fibonacci 61.8% 8.88
Fibonacci 50% 7.94
Fibonacci 38.2% 7.00
Last Price 5.72
52-Week Low 3.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar